← Eichor
Condition: Immunotherapy Active Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Immunotherapy Active

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER
NA · 1 location(s) · Medical University of Graz · NCT07267000Promoting Response to IMmunotherapy by Exercise in Patients With Advanced Renal Cell Carcinoma
NA · 2 location(s) · Radboud University Medical Center · NCT07680556C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT04099797Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07589530Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Inte
Phase 3 · 1 location(s) · Fujian Medical University Union Hospital · NCT06441110An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).
Phase 3 · 1 location(s) · Ruijin Hospital · NCT0633906018F-FLUC PET/MR in Patients With Brain Mets
Phase 3 · 1 location(s) · University of Wisconsin, Madison · NCT06159335INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma
Phase 3 · 1 location(s) · Tongji Hospital · NCT07002346GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Phase 1/Phase 2 · 12 location(s) · GI Innovation, Inc. · NCT04977453A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lu
Phase 2 · 43 location(s) · Johnson & Johnson Enterprise Innovation Inc. · NCT06667908A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC
Phase 2 · 3 location(s) · GrandPharma (China) Co., Ltd. · NCT07334483HER-2 B Cell Peptide Vaccine
Phase 1 · 1 location(s) · Pravin T.P Kaumaya · NCT06414733A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T
Phase 1/Phase 2 · 13 location(s) · Cabaletta Bio · NCT04422912Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy
Phase 1 · 1 location(s) · Fujian Medical University Union Hospital · NCT07551037Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma
NA · 1 location(s) · Universitätsklinikum Hamburg-Eppendorf · NCT07564570A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional
Phase 1/Phase 2 · 11 location(s) · GI Innovation, Inc. · NCT05824975A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Pliant Therapeutics, Inc. · NCT06270706Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Act
Phase 1 · 6 location(s) · Jun Zhou · NCT07584954Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)
Phase 1 · 1 location(s) · West China Hospital · NCT07538479Study Evaluating the Efficacy of the myDIET Software Tool in the Nutritional Management of Patients With Localized and R
Phase 2 · 1 location(s) · Centre Leon Berard · NCT06385691Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
Phase N/A · 2 location(s) · University Hospital, Montpellier · NCT06627595Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
Phase 2 · 1 location(s) · Ashutosh Kumar Tewari · NCT06343077FS222 First in Human Study in Patients With Advanced Malignancies
Phase 1 · 21 location(s) · invoX Pharma Limited · NCT04740424Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell
NA · 1 location(s) · Fred Hutchinson Cancer Center · NCT06983899TNBC Gut Microbiota During Neoadjuvant Treatment
NA · 1 location(s) · Scripps Health · NCT06610097A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Phase 1/Phase 2 · 26 location(s) · AC Immune SA · NCT05462106DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
Phase 1/Phase 2 · 7 location(s) · University College, London · NCT04106115A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
Phase 1 · 8 location(s) · FBD Biologics Limited · NCT05892718IDOV-Immune for Advanced Solid Tumors
Phase 1 · 5 location(s) · ViroMissile, Inc. · NCT06910657CAR-T Cells for HIV Infection
Phase 1/Phase 2 · 2 location(s) · Steven Deeks · NCT04648046
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.